
- Applied Clinical Trials-04-01-2008
- Volume 0
- Issue 0
EU Seeks Hematology Guidance
Europe aims to create new regulations regarding hematological malignancies.
The EMEA is proposing to create new guidance on hematological malignancies. The agency's idea arises from the recent increased activity in developing new treatments for hematological malignancies, including rare disorders and small target populations. This has led to a rise in applications for marketing authorization, but above all to numerous requests for scientific advice from the agency, prior to submitting an application.
The new guidance will deal with special considerations such as allogeneic stem cell transplantation and its consequences in relation to designation of primary endpoints. It will also take account of the use of molecular techniques in response evaluations, treatments administered with curative or palliative intent, and progression or relapse off-therapy. It will focus on the design of confirmatory studies, and will provide separate discussion of major diagnoses such as the acute leukemias, myelodysplastic syndromes, low and high grade lymphomas, and malignant myeloma. Other, rarer conditions will be covered conceptually. Most of the work will be carried out during this year—and anyone wanting to give their views to the agency is invited to do so until the end of this month.—Peter O'Donnell
Articles in this issue
over 17 years ago
Buenos DIAs from Barcelonaover 17 years ago
Drug Pooling: Power and Pitfallsover 17 years ago
A Pandora's Box for Clinical Trials?over 17 years ago
A Carrot and Sticks Approachover 17 years ago
Research, Investigator Conduct Under Scrutinyover 17 years ago
Global Newsover 17 years ago
Marked Decline in Clinical Operations Productivityover 17 years ago
Key Factors in CRO Selectionover 17 years ago
Animating Informed Consentover 17 years ago
The Local Central Lab ModelNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.